Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1369L |
[Sar9,Met(O2)11]-Substance P acetate
[Sar9,Met(O2)11]-Substance P acetate(110880-55-2 free base) |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
[Sar9,Met(O2)11]-Substance P acetate(110880-55-2 free base) 是一种速激肽 NK1 受体选择性激动剂。它是一种选择性速激肽 NK1 受体激动剂。它和 septide(每只大鼠 10-100 pmol,i.c.v.)在增加平均动脉血压 (MAP) 和心率 (HR),但它们的时间进程不同。两种激动剂都以剂量依赖性方式增加洗脸和吸鼻,而它是一种产生美容效果的化合物。 | |||
T7828 |
[Sar9,Met(O2)11]-Substance P
Bhsar-sp,NA,精氨酰-脯氨酰-赖氨酰-脯氨酰-谷氨酰-谷氨酰-苯丙氨酰-苯丙氨酰-SAR-亮氨酸-蛋氨酸[O2]-胺 |
Neurokinin receptor | GPCR/G Protein; Neuroscience |
[Sar9,Met(O2)11]-Substance P (NA) 是选择性速激肽NK1受体激动剂。 | |||
TP1369 |
[Sar9,Met(O2)11]-Substance P TFA(110880-55-2,free)
[Sar9,Met(O2)11]-Substance P TFA |
||
[Sar9,Met(O2)11]-Substance P TFA is a selective tachykinin NK1 receptor agonist.[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissi | |||
T9052 |
XL092
CL-092,JUN04542 |
VEGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
XL092 (JUN04542) 是一种ATP 竞争性的、口服有效的多受体酪氨酸激酶 (RTKs) 抑制剂,在细胞分析中的MET (IC50:15 nM)、VEGFR2 (IC50:1.6 nM)、AXL (IC50:3.4 nM) 和 MER (IC50:7.2 nM)。它具有抗肿瘤作用,具有用于研究激酶依赖性疾病的潜力。 | |||
T25098 |
Antiflammin P2
Hdmnkvldl,Antiflamin 2,His-asp-met-asn-lys-val-leu-asp-leu |
||
Antiflammin P2 is a nonapeptide fragment of lipocortin I which has no phospholipase A2 inhibitory and anti-inflammatory activity. | |||
T75769 | [Sar9,Met(O2)11]-Substance P TFA | ||
[Sar9,Met(O2)11]-Substance P TFA 是一种选择性的速激肽NK1受体激动剂。 | |||
TQ0210 |
Savolitinib
AZD-6094,Volitinib,沃利替尼,赛沃替尼,HMPL-504 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Savolitinib (Volitinib) 是一种高效选择性、口服生物利用度c-Met 抑制剂,能够抑制 c-Met (IC50:5 nM)和 p-Met (IC50:3 nM)。它以 ATP 竞争的方式选择性结合并抑制 c-Met 的激活,破坏 c-Met 信号转导途径,具有抗肿瘤作用。 | |||
T77575 |
P-gb-IN-1
|
P-gp | Membrane transporter/Ion channel; Neuroscience |
P-gb-IN-1 是一种有效的 P-糖蛋白 (P-gp) 抑制剂,通过抑制 P-gp 外流展现出逆转活性。P-gb-IN-1 通过与残基 Asn 721 和 Met 986 形成氢键相互作用从而显示出对 P-gp 的抑制作用。P-gb-IN-1 在 MCF-7/ADR 细胞中显示出低毒性。 | |||
TP1862L |
[Sar9] Substance P acetate(77128-75-7 free base)
|
Neurokinin receptor | GPCR/G Protein; Neuroscience |
[Sar9] Substance P acetate(77128-75-7 free base) 是一种 NK-1 受体激动剂。 rNK1 特异性激动剂 [Sar-9,Met(O2)11]-SP 模拟了 SP 对孕酮代谢的作用。 | |||
T76452 |
Gly-Leu-Met-NH2
|
||
Gly-Leu-Met-NH2 是 Substance P (Substance P ) 的 C 端三肽。Substance P 是一种神经肽。 | |||
T15384 |
Glesatinib
MGCD265 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC. | |||
T76449 |
Substance P (alligator)
|
||
Substance P (alligator),一种从鳄鱼中提取的神经肽,其氨基酸序列为Arg-Pro-Arg-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2。 | |||
T15383 |
Glesatinib hydrochloride
MGCD265 hydrochloride |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC. | |||
T70456 |
Nolpitantium Free Base
|
||
Nolpitantium Free Base is a highly selective nonpeptide antagonist of neurokinin-1 (NK1) receptor. Nolpitantium potently, selectively and competitively inhibited substance P binding to NK1 receptors from various animal species, including humans. In vitro, it was a potent antagonist in functional assays for NK1 receptors such as [Sar9, Met(O2)11]substance P-induced endothelium-dependent relaxation of rabbit pulmonary artery and contraction of guinea-pig ileum. Up to 1 mkM, Nolpitantium had no eff... | |||
TP1862 |
[Sar9] Substance P
|
||
[Sar9]-Substance P is one of NK-1 receptor agonist. The action of SP on progesterone metabolism was mimicked by the rNK1-specific agonist [Sar-9,Met(O2)11]-SP. | |||
T29186 |
YM49598
YM-49598,YM 49598 |
||
YM49598 is a tachykinin receptor antagonist. YM49598 exhibited high binding affinities at NK(1) (pK(i) = 9.09 +/- 0.02) and NK(2) (pK(i) = 9.94 +/- 0.03) receptors, respectively. YM49598 was almost inactive but produced a potent inhibition (IC(50) = 11 +/ |